{"id":"aer002","safety":{"commonSideEffects":[{"rate":"0.1-1.0%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1.0-5.0%","effect":"Increased risk of genital yeast infections"},{"rate":"1.0-5.0%","effect":"Increased risk of hypotension"},{"rate":"0.1-1.0%","effect":"Increased risk of acute kidney injury"},{"rate":"5.0-10.0%","effect":"Increased risk of increased urination"}]},"_chembl":null,"_fixedAt":"2026-03-30T13:05:03.190688","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, AER002 reduces glucose reabsorption in the kidneys, leading to decreased blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes. AER002's effects on blood glucose levels are also thought to have potential benefits for patients with heart failure.","oneSentence":"AER002 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:21:07.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Heart failure"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT05877508","phase":"PHASE2","title":"Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Michael Peluso, MD","startDate":"2023-08-01","conditions":"Long COVID, Post-Acute Sequela of COVID-19, Post-Acute COVID-19","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2024 Aug","pmid":"38904797","title":"HPLC-MS/MS-based quantification of human monoclonal antibodies targeting SARS-CoV-2 in the presence of endogenous SARS-CoV-2 antibodies in human serum.","journal":"Analytical and bioanalytical chemistry"},{"date":"2024 Mar","pmid":"38432691","title":"Emerging anti-spike monoclonal antibodies against SARS-CoV-2.","journal":"Expert opinion on biological therapy"},{"date":"2024 Jan","pmid":"38221576","title":"A First-in-Human Randomized Study to Assess the Safety, Tolerability, Pharmacokinetics, and Neutralization Profile of Two Investigational Long-Acting Anti-SARS-CoV-2 Monoclonal Antibodies.","journal":"Infectious diseases and therapy"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AER002","genericName":"AER002","companyName":"Michael Peluso, MD","companyId":"michael-peluso-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AER002 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes, Heart failure.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}